evipedia.aidev
← Back

L-Lysinate for Health & Longevity

Evidence Review created on 08/23/2026 using AI4L / Grok 4.5

Also known as: L-lysine, L-lysine hydrochloride, L-lysine HCl, L-lysine monohydrochloride, L-Lysine lysinate, lysine salt, (S)-2,6-diaminohexanoate, L-lysine (carboxylate salt), magnesium L-lysinate, calcium L-lysinate, zinc L-lysinate, L-2,6-diaminohexanoic acid

Motivation

L-Lysinate is the salt form of L-lysine, an essential amino acid the body cannot make and must obtain from food or supplements. After it is swallowed, the salt breaks apart and free L-lysine enters the blood — the same amino acid supplied by meat, dairy, fish, and legumes. Interest among health- and longevity-oriented adults comes from its role in collagen and from decades of research on recurrent cold sores.

Most people who eat enough animal protein already meet the lysine requirement. Extra L-lysinate became a consumer intervention after 1970s cold-sore studies, later trials in communities whose grain-heavy diets supply little lysine, and mineral-lysine salts sold as sources of magnesium, calcium, and zinc. The question is whether amounts above diet change the outcomes people actually use it for.

This review examines the human evidence on oral L-lysinate and the free L-lysine it becomes: how it works, which benefits and harms have been measured, which factors change the signal, and how protocols, sourcing, and monitoring are described in the literature.

Benefits - Risks - Protocol - Conclusion

High-level overviews of L-lysinate and of the free L-lysine it supplies after oral intake.

Rhonda Patrick, Andrew Huberman, and Lifespan.io had no dedicated L-lysinate or L-lysine supplement overviews.

Grokipedia

  • Lysine

    Encyclopedia entry on lysine chemistry, collagen cross-links, carnitine, and supplementation when cereal diets are lysine-short — the amino acid L-lysinate supplies.

No dedicated Grokipedia article for L-Lysinate was found.

Examine

  • Lysine

    Evidence grades for oral lysine, with cold sores as the main outcome and a practical divided-dose schedule up to 2 g/day.

No dedicated Examine article for L-Lysinate was found.

ConsumerLab

  • L-Lysine Supplements Review

    Independent product tests plus a plain-language summary of herpes, labeling traps for lysine hydrochloride, and typical 1–3 g doses.

No dedicated ConsumerLab article for L-Lysinate was found.

Systematic Reviews

Systematic reviews of oral L-lysine — the circulating amino acid supplied by L-lysinate — covering cold-sore prevention and supplemental safety.

No systematic review dedicated to L-lysinate (as distinct from L-lysine) was found. Systematic reviews of blood-pressure, calcium-retention, or anxiety outcomes for supplemental lysine are unrepresented.

Mechanism of Action

L-Lysinate is the carboxylate salt of L-lysine, an essential amino acid humans cannot synthesize. After oral intake the salt dissociates to circulating L-lysine, the same species measured in hydrochloride trials. L-lysine enters cells through cationic amino-acid transporters (CAT-1/SLC7A1, the main lysine/arginine carrier, and related y+ systems) shared with arginine and ornithine. High lysine therefore competes with arginine for uptake and can raise arginase (the enzyme that breaks down arginine) activity, lowering arginine available for viral capsid synthesis and for nitric oxide (a blood-vessel relaxing gas) production. In connective tissue, lysyl hydroxylase converts collagen lysine residues to hydroxylysine, which cross-links collagen and elastin. Lysine is also a precursor of carnitine, which shuttles fatty acids into mitochondria.

Free lysine can act as a chemical chaperone and competing glycation substrate. Oral lysine delays gastric emptying and increases intestinal fluid dose-dependently. Plasma free lysine typically peaks within one to two hours and falls over several hours (half-life two to three hours). It is not metabolized by cytochrome P450 enzymes (the main liver enzymes that break down many drugs); the liver breaks it down through the saccharopine pathway (the main lysine-degradation route) via aminoadipic semialdehyde synthase (AASS). It distributes into the free amino-acid pool, muscle, and gut. Mineral L-lysinate chelates (magnesium, calcium, zinc) deliver the mineral; the European Food Safety Authority (EFSA) accepted those salts as bioavailable mineral sources. Competing views hold extra lysine is redundant once intake meets about 30 mg/kg, versus a high lysine-to-arginine ratio having distinct antiviral and mineral-retention effects.

Historical Context & Evolution

L-lysine was isolated as a protein hydrolysis product in the late nineteenth century and classified as essential when human nitrogen-balance work showed that diets lacking it would not maintain protein status. Industrial fermentation later made crystalline L-lysine cheap enough for animal feed and, from the 1970s, for human tablets. The carboxylate salt — L-lysinate — appears in mineral chelates (magnesium, calcium, and zinc L-lysinate) and as the anion paired with some drugs; oral L-lysinate still yields free L-lysine.

The health-optimization use began with tissue-culture work showing that arginine supported herpes simplex replication and that lysine antagonized that effect. Small oral trials followed. Griffith’s 1987 multicenter trial of 3 g/day L-lysine reported fewer recurrences, milder symptoms, and faster healing, while DiGiovanna and Blank (1984) found no benefit at 1.2 g/day. That dose split, not a later “debunking,” still defines the debate. In parallel, Civitelli (1992) reported that L-lysine increased intestinal calcium absorption and blunted calciuria (urinary calcium loss), which pulled the amino acid into osteoporosis discussions without fracture trials. Smriga and colleagues then tested lysine fortification in lysine-short communities (anxiety, infectious morbidity, blood pressure), shifting the claim from “everyone needs extra lysine” to “extra lysine matters when the diet is short.” Linus Pauling’s lysine-plus-ascorbate idea for lipoprotein(a) never gained confirmatory human outcome trials. Current practice still sits on those older herpes studies, one Ghana blood-pressure trial, and safety syntheses that set a several-gram daily ceiling — not on a settled consensus.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: herpes-recurrence data are small, older, and internally conflicted; blood-pressure and infectious-morbidity findings come from single trials in lysine-inadequate diets rather than replicated clinical endpoints in protein-replete adults.

Medium 🟩 🟩

Lower blood pressure when dietary lysine is low

In adults whose usual cereal-based diet supplies little lysine, 1 g/day of oral lysine for 112 days lowered systolic blood pressure (the upper number in a blood-pressure reading) in a randomized, double-blind Ghanaian trial. The proposed mechanism is correction of lysine inadequacy plus effects on stress chemistry, not a general antihypertensive drug action. The signal appeared in people already hypertensive and not on blood-pressure medication; it is not a finding in lysine-replete Western diets. Women in the same trial showed a smaller, non-significant change.

Magnitude: Hypertensive men’s mean systolic pressure fell from 146.11 to 128.95 mmHg after 1 g/day for 112 days; placebo-group men changed from 145.79 to 142.79 mmHg (Vuvor et al., 2017).

Fewer infectious illnesses when dietary lysine is low

The same research program found that 1 g/day lysine reduced diarrheal episodes in children and coryza (head-cold) episodes in men in peri-urban Accra households with a high prevalence of lysine inadequacy. Mechanisms proposed include better gut repair, effects on serotonin receptors, and improved host protein status — not a direct antimicrobial drug effect. This is a single community randomized trial, so it does not establish a longevity benefit for protein-replete adults.

Magnitude: Children had an odds ratio (odds of the event versus placebo) of 0.52 for diarrheal episodes (19 vs 35 events) and 0.44 for days ill; men had an odds ratio of 0.60 for coryza and 0.51 for days ill (Ghosh et al., 2010).

Low 🟩

Fewer herpes simplex recurrences ⚠️ Conflicted

Oral lysine may reduce cold-sore recurrences by competing with arginine. Griffith (1987) found fewer outbreaks at 3 g/day; DiGiovanna (1984) and Cochrane 2015 did not confirm benefit. Net reading: an unreplicated, dose-dependent signal in older trials, not confirmed by the Cochrane synthesis.

Magnitude: Griffith 1987 reported 2.4 fewer recurrences and 2.1 days faster healing at 3 g/day versus placebo in 52 completers (Griffith et al., 1987; DiGiovanna & Blank, 1984; Chi et al., 2015).

Greater intestinal calcium absorption

A short metabolic study in osteoporotic adults found that 800 mg/day L-lysine increased labeled-calcium absorption; 400 mg with a calcium load also reduced urinary calcium loss. No trial has shown higher bone density or fewer fractures.

Magnitude: 47Ca fractional absorption increased after 800 mg/day L-lysine versus other amino acids in 45 osteoporotic patients; the literature reports no numeric absorption change, and no bone-density outcome is reported (Civitelli et al., 1992).

Lower anxiety under lysine-inadequate or combined-amino-acid protocols

Wheat lysine fortification reduced anxiety in lysine-short Syrian families (Smriga et al., 2004). A one-week lysine-plus-arginine trial lowered anxiety and male salivary cortisol (Smriga et al., 2007). Lysine-only data in protein-replete adults remain thin.

Magnitude: Anxiety fell with wheat lysine fortification in lysine-short Syrian families and with one-week lysine-plus-arginine in healthy adults; the literature reports no standardized effect size for lysine-only supplementation in lysine-replete adults.

Speculative 🟨

Collagen quality, wound repair, and skin structure

Lysine is required for collagen cross-links, so deficiency impairs connective tissue. Extra L-lysinate in protein-replete people has no controlled human outcome data for wounds, skin, or joints.

Less protein glycation

L-lysine can compete for glycation and act as a chaperone. A small diabetes trial reported lower glycation markers at 3 g/day; those markers are not validated clinical surrogates (Mirmiranpour et al., 2016).

Carnitine synthesis and fat oxidation

Lysine plus methionine are carnitine precursors. Raising oral L-lysinate to increase carnitine-mediated fat oxidation in replete adults remains mechanistic only.

Benefit-Modifying Factors

  • Baseline lysine intake: Benefits on blood pressure, infectious morbidity, and anxiety clustered in cereal-based diets providing roughly 34–41 mg lysine per gram of protein, below the adult target of about 45 mg/g. Protein-replete omnivores start from a different baseline.

  • Baseline biomarkers: The Ghana blood-pressure drop appeared in people already at hypertensive-range systolic values; optional plasma lysine is a weak intake marker and is not required to judge a benefit.

  • Herpes recurrence frequency and dose: Older positive herpes trials enrolled people with frequent recurrences and used ≥1.2–3 g/day. Sub-gram doses and people with rare outbreaks are the groups in which trials did not show a signal.

  • Sex: In the Ghana hypertension trial, the systolic drop was statistically significant in men and not in women. Anxiety-hormone changes in the Japanese lysine-plus-arginine study were also more apparent in men (Smriga et al., 2007).

  • Age and anabolic efficiency: Older adults use dietary protein less efficiently per meal. Extra lysine can raise the quality of a low-lysine plant-heavy pattern; it does not replace total protein or leucine for muscle protein synthesis.

  • Pre-existing metabolic disease: The glycation trial enrolled type 2 diabetes. That context does not generalize to euglycemic (normal blood-sugar) longevity protocols.

  • Transporter genetics: Biallelic SLC7A7 variants cause lysinuric protein intolerance (failure of lysine/arginine/ornithine transport); extra oral lysine is not a benefit in that disease and is a contraindication.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the pooled safety review of 71 human studies did not show a statistically significant increase in gastrointestinal events, and the serious kidney-injury signal is a single case report rather than replicated trial adverse events.

Medium 🟥 🟥

Gastrointestinal symptoms and delayed gastric emptying

The main adverse events in oral lysine trials are nausea, abdominal pain, and diarrhea. Hayamizu’s systematic review of 71 studies found those symptoms drove a 6 g/day safety ceiling, yet the pooled risk ratio (how many times as often events occurred versus control) was 1.02 and not statistically significant. A magnetic resonance imaging (MRI) dose-finding study showed L-lysine delays gastric emptying by about 4 min per gram and increases intestinal fluid — an effect that can produce fullness, nausea, or loose stools at multi-gram bolus doses.

Magnitude: Pooled gastrointestinal risk ratio 1.02 (95% confidence interval, the range likely to contain the true value, 0.96–1.07); gastric half-emptying time increased 4 min/g L-lysine; intestinal fluid increased 0.4 mL/min/g (Hayamizu et al., 2020; Baruffol et al., 2014).

Low 🟥

Fanconi syndrome and tubulointerstitial nephritis after prolonged high intake

A 44-year-old woman developed Fanconi syndrome (a proximal-tubule leak of glucose, amino acids, and phosphate) and kidney-filter inflammation after years of oral L-lysine for herpes prevention, later progressing toward chronic kidney disease. This is a single case report, not a trial signal.

Magnitude: Not quantified in available studies. The literature contains one detailed human case after multi-year L-lysine ingestion, without an incidence rate from controlled trials (Lo et al., 1996).

Speculative 🟨

Reduced arginine-dependent nitric oxide signaling

Lysine shares transporters with arginine, so high doses could in theory lower nitric oxide. A human infusion study found lysine did not reproduce arginine’s vessel widening (Smulders et al., 1997).

Gallbladder disease and calcium co-load

Mailoo & Rampes, 2017 flagged theoretical gallbladder and cardiovascular cautions. Lysine can raise calcium absorption, so stacking high-dose calcium is a theoretical hypercalcemia (high blood calcium) risk. Neither is documented as a trial adverse-event cluster.

Risk-Modifying Factors

  • Dose and bolus size: Gastrointestinal symptoms and delayed emptying scale with grams per sitting. The safety synthesis’s 6 g/day ceiling is for healthy adults; multi-gram single doses are the practical trigger.

  • Baseline kidney function: The Fanconi case and amino-acid load both point to the proximal tubule. Reduced eGFR (estimated glomerular filtration rate, a kidney-filter score) raises the cost of a chronic high amino-acid load.

  • Lysinuric protein intolerance (SLC7A7): This rare transporter defect already mishandles lysine, arginine, and ornithine; extra oral lysine is harmful, not dose-adjustable.

  • Hepatic impairment and hyperlysinemia: Drugs.com lists hepatic and renal impairment as reasons to avoid supplementation; inborn hyperlysinemia/hyperlysinuria (excess lysine in blood or urine from a metabolic defect) is an absolute contraindication.

  • Age: Older adults have less kidney reserve and slower gastric emptying, so the same gram dose is a larger relative load.

  • Sex: Trial adverse-event reporting has not shown a consistent female-specific toxicity; the Ghana blood-pressure signal was stronger in men, which is a benefit modifier more than a risk modifier.

Key Interactions & Contraindications

  • Calcium salts (calcium carbonate, calcium citrate): Caution. Lysine can increase intestinal calcium absorption and reduce calciuria; stacked high-dose calcium raises a theoretical hypercalcemia risk. Separate megadoses and monitor serum calcium if both are used chronically.

  • Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin): Caution. Monographs warn of increased aminoglycoside nephrotoxicity when lysine is co-administered. Avoid stacking during aminoglycoside courses.

  • L-arginine and high-arginine supplements (L-arginine, citrulline, some nitric-oxide boosters): Caution. Shared y+ transport can blunt the high lysine-to-arginine ratio used for antiviral protocols; timing separation does not fully remove competition if both are taken daily.

  • Other cationic amino acids (ornithine, high-dose histidine): Monitor. Shared transporters can change uptake of each amino acid; clinical consequence is uncertain at mixed-supplement doses.

  • Oral calcium-channel blockers (verapamil, diltiazem) and anticholinergics (diphenhydramine, oxybutynin): Caution at multi-gram lysine boluses because lysine itself delays gastric emptying; the clinical consequence is more nausea or altered co-drug absorption.

Populations who should avoid L-Lysinate:

  • Lysinuric protein intolerance (SLC7A7-related)
  • Hyperlysinemia or hyperlysinuria
  • Glutaric acidemia type I (a rare organic-acid metabolism disorder)
  • Advanced chronic kidney disease (eGFR <30 mL/min/1.73 m², roughly Kidney Disease: Improving Global Outcomes stage 4–5) unless a clinician is already managing amino-acid intake
  • Decompensated hepatic failure (Child-Pugh Class C)
  • Known lysine hypersensitivity (rare)

Risk Mitigation Strategies

  • Safety-synthesis ceiling: The 71-study review set 6 g/day as the no-observed-adverse-effect level in healthy adults, defined by the gastrointestinal events that appeared as dose rose.

  • Split daily amount: Trial and MRI protocols divided 1–3 g into two or three doses with meals, matching the ~4 min/g gastric-emptying delay and lower nausea than a single bolus.

  • Low starting amount: Protocols for sensitive guts often began at 500–1,000 mg/day for several days before stepping up, limiting acute abdominal pain and diarrhea.

  • Aminoglycoside co-administration: Monographs warn of added kidney-tubule stress when lysine is taken during gentamicin, tobramycin, or amikacin courses.

  • Calcium co-load: Because lysine can raise calcium absorption, stacked megadose calcium is the setting of the theoretical hypercalcemia (high blood calcium) risk.

  • Kidney history before long high-dose use: The Fanconi case followed multi-year high intake; a baseline metabolic panel and eGFR before multi-gram, multi-month protocols is the surveillance those reports imply.

Therapeutic Protocol

  • Common supplemental range: Trials and monographs cluster at 1–3 g/day of L-lysine (the amount L-lysinate supplies after dissociation), with herpes protocols sometimes using 3 g/day and community trials using 1 g/day.

  • Herpes-oriented schedule: Older positive trials used 1,248–3,000 mg/day; Mailoo and Rampes read doses under 1 g/day as ineffective. Acute-treatment evidence is weaker than prevention evidence.

  • Lysine-inadequate diet schedule: The Ghana trials used 1,000 mg/day in two 500 mg doses for 112 days in people not on antihypertensives.

  • Timing: Split doses with meals to blunt gastric-emptying delay. Some herpes protocols use between-meal dosing to favor a high lysine-to-arginine ratio; that timing is empirical, not pharmacokinetic dogma.

  • Half-life and splitting: Plasma free lysine peaks in about 1–2 hours and declines over several hours (approximate half-life 2–3 hours), which is why multi-gram daily amounts are usually split rather than taken once.

  • Sex: No separate labeled dose by sex. Blood-pressure and some anxiety-hormone signals were stronger in men; protocols in the literature still used the same milligram dose.

  • Age: Older adults often use protein less efficiently and have less kidney reserve; staying toward 1–2 g/day split, not 6 g boluses, matches that physiology.

  • Genetics: SLC7A7 disease excludes supplementation. No common pharmacogenetic dose split is established for lysine.

  • Baseline diet: If habitual intake already exceeds ~45 mg lysine/g protein, extra L-lysinate is a pharmacologic experiment, not nutrient replacement.

  • Baseline biomarkers: Kidney-filter and serum-calcium values change whether a multi-gram protocol is a mineral or kidney-load experiment; plasma lysine is optional and a poor habitual-intake marker.

  • Competing approaches: Conventional herpes prevention uses oral antivirals (acyclovir, valacyclovir, famciclovir). Integrative protocols use lysine plus arginine restriction. Mineral L-lysinate chelates are a different goal (delivering magnesium, calcium, or zinc).

Discontinuation & Cycling

  • Duration of use: Not inherently lifelong. Community trials ran about 16 weeks; herpes prevention trials ran months. Safety data exist out to years, but long high-dose use is the setting of the Fanconi case.

  • Withdrawal: No recognized withdrawal syndrome. Plasma lysine returns toward dietary baseline within hours to a day after stopping.

  • Tapering: Not required for physiologic dependence. Stepping down a multi-gram dose over a few days can ease rebound gut motility if gastric emptying was delayed.

  • Cycling: No evidence that cycling preserves efficacy. Herpes users sometimes raise the dose at prodrome (early warning symptoms) and lower it between outbreaks; that is a pragmatic pattern, not a receptor-desensitization protocol.

  • After stopping herpes prevention: Recurrence frequency may return to the person’s baseline; older trials that withdrew lysine reported more lesions as serum lysine fell.

Sourcing and Quality

  • What L-lysinate is on a label: True L-lysinate is the lysine carboxylate salt, often as a mineral chelate (magnesium, calcium, or zinc L-lysinate). Standalone “L-lysine” products are usually L-lysine hydrochloride, which still yields free L-lysine after ingestion.

  • Hydrochloride math: About 20% of L-lysine HCl by weight is chloride. Labels that quote the salt weight overstate the amino acid; milligrams of L-lysine (free base) are the amount that matches trial doses.

  • Third-party testing: USP, NSF, or ConsumerLab-tested lots are the quality markers used for this category. ConsumerLab’s 2023 lysine tests found listed amounts present, with large price differences per 1,000 mg.

  • Mineral chelates: EFSA, 2008 accepted magnesium, calcium, and zinc L-lysinate as mineral sources. Those products are dosed to elemental mineral, not to a 1–3 g lysine target.

  • Brands that appear in testing or clinic protocols: NOW, Pure Encapsulations, Thorne, Life Extension, and Carlson showed up in ConsumerLab’s lysine review or common clinical catalogs. No brand is uniquely evidence-based.

  • Avoid: Products that hide salt versus free-base math, cat-formulated lysine as a human dose reference, or drug lysinate salts (ibuprofen lysinate, ketoprofen lysinate, aspirin lysinate), which are different medicines.

Practical Considerations

  • Time to effect: Blood-pressure and morbidity trials used ~16 weeks. Herpes prevention, when it worked, was assessed over months, not days. Acute outbreak shortening is not well supported.

  • Label pitfall: Buying “1,000 mg L-lysine HCl” that is only ~800 mg lysine is the common sourcing error ConsumerLab flags.

  • Arginine pitfall: Taking L-arginine, a handful of nuts, or a nitric-oxide booster alongside a herpes-oriented lysine protocol undercuts the intended amino-acid ratio.

  • Regulatory status: In the United States L-lysine/L-lysinate is a dietary supplement, not a Food and Drug Administration (FDA)-approved drug for herpes, hypertension, or osteoporosis. Drug lysinate salts are separate approved medicines.

  • Cost and access: Crystalline lysine is inexpensive (often well under $0.30 per gram from tested products). Access is not a limiting factor in ordinary retail channels.

Interaction with Foundational Habits

  • Sleep: Direct sleep-promoting data for L-lysinate are lacking. Indirectly, fewer cold-sore recurrences or lower stress chemistry could help sleep in the subgroups that see those signals; large boluses that delay gastric emptying can worsen nighttime fullness.

  • Nutrition: Direct interaction. Animal protein is already lysine-rich; extra L-lysinate matters most on cereal-heavy, low-legume patterns. High-arginine foods (nuts, seeds, chocolate) compete for the same transporters. Pairing with megadose calcium changes mineral handling.

  • Exercise: Direct anabolic role of dietary lysine as an essential amino acid for muscle protein; extra isolated L-lysinate is not a hypertrophy drug and does not replace leucine-rich protein around training. No evidence that it blunts adaptation.

  • Stress management: Indirect and possibly potentiating. Lysine fortification and lysine-plus-arginine protocols lowered anxiety and some cortisol measures in lysine-short or mixed-amino-acid settings. Stress is also a classic herpes-reactivation trigger, so stress skills and lysine are overlapping, not redundant, levers.

Monitoring Protocol & Defining Success

Before a multi-month L-lysinate protocol, a baseline metabolic panel (electrolytes, kidney, and liver) and a blood-pressure reading establish whether the kidney-tubule and mineral-handling risks are already in play. People using it for cold-sore prevention add a simple outbreak diary (date, duration, severity). People using it because their diet is plant-heavy can estimate lysine from a diet record rather than a plasma amino-acid level, which is a poor marker of habitual intake. Repeat the metabolic panel at 4–8 weeks after reaching a steady dose, then every 6–12 months if use continues, sooner if nausea, polyuria (large urine volume), or bone pain appears. Success is defined by the intended endpoint — fewer documented recurrences, a sustained blood-pressure change in a previously lysine-short eater, or simply no lab drift — not by pushing plasma lysine to a lab “high.”

Biomarker Optimal Functional Range Why Measure It? Context/Notes
eGFR (estimated glomerular filtration rate) ≥90 mL/min/1.73 m²; investigate a fall from personal baseline Detects kidney-filter loss relevant to the Fanconi case Conventional chronic kidney disease (CKD) cut is <60; a drop while on high-dose lysine is more informative than a single conventional “normal”
Serum creatinine Stay near personal baseline (often ~0.6–1.1 mg/dL) Proximal-tubule and filter injury Fasting not required; interpret with eGFR and muscle mass
BUN Often ~10–18 mg/dL in functional practice Amino-acid nitrogen load Blood urea nitrogen; conventional upper limits run higher (~20 mg/dL); rising BUN with stable creatinine can reflect protein/amino-acid load
Serum calcium ~9.0–10.0 mg/dL Lysine can raise calcium absorption Conventional range ~8.6–10.2 mg/dL; pair with albumin; fasting morning draw preferred if stacked with calcium
Serum phosphate No established lysine-specific target; track personal baseline (conventional ~2.5–4.5 mg/dL) and watch a fall Fanconi pattern includes phosphate wasting Abnormal with glucosuria/aminoaciduria (glucose or amino acids in urine) needs a full tubule workup
Plasma lysine (optional) Typical fasting ~150–250 µmol/L Thein & Hurt, 1984 linked fewer lesions above 165 nmol/mL (165 µmol/L) Not a reliable intake marker; not required for routine use
Blood pressure Individual target; trial hypertensives started ≥140 mmHg systolic Endpoint in the Ghana lysine trial Seated, triplicated, same-time-of-day; not a substitute for medication in diagnosed hypertension

Qualitative markers:

  • Cold-sore or genital-herpes recurrence count, duration, and severity
  • Nausea, bloating, or change in stool after dose increases
  • Energy and training recovery if the goal is protein quality on a plant-heavy diet
  • Stress reactivity if that was the reason for use

Emerging Research

  • Completed gut-physiology trial: The Effect of L-lysine on Human Gastrointestinal Secretion (n=6, completed) mapped dose-dependent gastric emptying and intestinal fluid and underpins the split-dose practical point.

  • Lysine bioavailability from food: Metabolic Availability of Lysine From Barley in Young Adult Men (n=7, not yet recruiting) could refine how much supplemental L-lysinate is redundant when the staple cereal changes.

  • No large modern herpes trial: The herpes claim still rests on 1980s studies. A well-powered, dose-stratified prevention trial could strengthen or erase that use; none is prominently recruiting.

  • Osteoporosis as an open clinical question: Holeček (2025) flags lysine in osteoporosis therapy as a research priority. Civitelli’s absorption data have not been followed by bone-density or fracture trials (Holeček, 2025).

  • Lysine–arginine immune and cardiovascular trade-offs: Pedrazini (2022) and Holeček (2025) both call for using lysine–arginine antagonism deliberately. That same antagonism could weaken arginine-dependent nitric oxide — a two-way research path, not only a pro-lysine one (Pedrazini et al., 2022).

  • Industry-linked safety agenda: The 6 g/day ceiling comes from International Council for Amino Acid Science workshop papers. Independent long-term kidney surveillance would test whether the Fanconi case is unique or under-ascertained (Cynober et al., 2020).

Conclusion

L-Lysinate is a salt of the essential amino acid L-lysine. After oral intake it supplies the same circulating amino acid as food lysine and as the common salt-form supplement used in trials. For adults who already eat enough high-quality protein, extra L-lysinate is not a broad longevity therapy. The clearest clinical signal is a blood-pressure drop in people whose usual diet is short of lysine, seen in one community trial, with fewer infections in lysine-short households in a related trial. Cold-sore prevention is the most popular use and the most contested: some older trials report fewer outbreaks at higher daily amounts, others do not, and a broad evidence review of cold-sore prevention did not confirm a benefit. Calcium handling can shift in short metabolic studies; bone-density outcomes are not established.

Safety reviews of dozens of human studies place day-to-day gut upset as the main complaint and a provisional ceiling near six grams extra per day in healthy adults. A single published kidney-injury case after years of high intake is the serious outlier. Industry-linked amino-acid groups funded much of the modern safety work; Life Extension sells L-lysine. Those conflicts do not erase the trials, but they belong next to them. In this risk-aware audience the compound is a narrow tool: possibly useful when diet lysine is low or when someone is tracking recurrent cold sores at gram-range doses, and otherwise an optional amino acid rather than a foundational longevity practice.

Top - Benefits - Risks - Protocol